Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Serum miR-22 may be a biomarker for papillary thyroid cancer.

Author information

Affiliations

  • 1. Department of Endocrinology and Metabolism, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
      Authors
    • Wang D 1
    • Guo C 1
    (2 authors)
  • 2. Department of Otolaryngology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
      Authors
    • Kong T 2
    • Mi G 2
    • Li J 2
    • Sun Y 2
    (4 authors)

Oncology Letters, 04 Feb 2019, 17(3):3355-3361
https://doi.org/10.3892/ol.2019.10011 PMID: 30867770 PMCID: PMC6396224

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

The present study aimed to examine whether serum microRNA (miR)-22 may be considered a potential biomarker to differentiate patients with papillary thyroid cancer (PTC) from healthy controls. Reverse transcription-quantitative polymerase chain reaction demonstrated that serum miR-22 expression was significantly enhanced in patients with PTC compared with in patients with benign thyroid nodules (BTN) and healthy controls. The expression levels of miR-22 were also increased in the thyroid tissue of patients with PTC compared with in patients with BTN. In addition, increased miR-22 in the serum of patients with PTC was positively associated with metastasis. Furthermore, miR-22 serum levels were increased in patients with PTC and the B-Raf proto-oncogene, serine/threonine kinase V600E mutation. Meanwhile, compared with patients with PTC and ≤1 ng/ml thyroglobulin (Tg)-fine needle aspiration biopsy (FNAB), serum miR-22 was significantly enhanced in patients with PTC and 1-10 ng/ml Tg-FNAB and >10 ng/ml Tg-FNAB. A receiver operating characteristic analysis demonstrated that serum miR-22 distinguished patients with PTC from patients with BTN and healthy controls. In conclusion, to the best of our knowledge, the present study was the first to demonstrate that upregulation of serum miR-22 may be used as a potential biomarker to distinguish patients with PTC from healthy controls.

Free full text 

Logo of onclettLink to Publisher's site
Oncol Lett. 2019 Mar; 17(3): 3355–3361.
Published online 2019 Feb 4. https://doi.org/10.3892/ol.2019.10011
PMCID: PMC6396224
PMID: 30867770

Serum miR-22 may be a biomarker for papillary thyroid cancer

Deping Wang,1 Changxiu Guo,1 Tingting Kong,2 Guangxi Mi,2 Jiantao Li,2 and Yuhan Sun2
Author information Article notes Copyright and License information Disclaimer

Associated Data

Data Availability Statement

Abstract

The present study aimed to examine whether serum microRNA (miR)-22 may be considered a potential biomarker to differentiate patients with papillary thyroid cancer (PTC) from healthy controls. Reverse transcription-quantitative polymerase chain reaction demonstrated that serum miR-22 expression was significantly enhanced in patients with PTC compared with in patients with benign thyroid nodules (BTN) and healthy controls. The expression levels of miR-22 were also increased in the thyroid tissue of patients with PTC compared with in patients with BTN. In addition, increased miR-22 in the serum of patients with PTC was positively associated with metastasis. Furthermore, miR-22 serum levels were increased in patients with PTC and the B-Raf proto-oncogene, serine/threonine kinase V600E mutation. Meanwhile, compared with patients with PTC and ≤1 ng/ml thyroglobulin (Tg)-fine needle aspiration biopsy (FNAB), serum miR-22 was significantly enhanced in patients with PTC and 1–10 ng/ml Tg-FNAB and >10 ng/ml Tg-FNAB. A receiver operating characteristic analysis demonstrated that serum miR-22 distinguished patients with PTC from patients with BTN and healthy controls. In conclusion, to the best of our knowledge, the present study was the first to demonstrate that upregulation of serum miR-22 may be used as a potential biomarker to distinguish patients with PTC from healthy controls.

Keywords: serum miR-22, papillary thyroid cancer, metastasis, biomarker

Introduction

Thyroid cancer is a common endocrine malignant tumor, the prevalence of which continues to increase worldwide (1). It has been reported that ~40,000 patients succumb to thyroid cancer per year, whereas ~300,000 new patients are diagnosed (1,2). Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and is characterized by a differentiated neoplasia (3). BRAF mutations are highly prevalent in thyroid carcinomas, especially B-Raf proto-oncogene serine/threonine kinase (BRAF)V600E (4). Distinguishing PTC from a benign thyroid nodule (BTN), including thyroid adenoma and classical nodular goiter, is crucial for clinicians. Currently, the two most common examination methods, ultrasound (US) and computed tomography, are used to analyze suspect thyroid nodules (5). Furthermore, pre-operative US-guided fine-needle aspiration cytology (FNAC) and intraoperative pathological examination are performed to further explore patients suspected of having PTC (5). However, FNAC sampling is very invasive and therefore limited since it requires multiple aspirations (6). Therefore, the identification of novel non-invasive biomarkers that do not require any invasive procedure is crucial for the early screening of PTC.

MicroRNAs (miRNAs/miRs) are small non-coding RNAs that are key regulators in various physiological and pathological processes, including cell proliferation, cell differentiation and cell death (7–10). Recent studies have revealed that, since circulating miRNAs are very stable in serum and plasma, and present high sensitivity and specificity, they may be considered as novel biomarkers (11,12). Xiong et al (13), demonstrated that miR-126-3p is a tumor suppressor in the progression of thyroid cancer. In addition, miR-375 has been reported to inhibit cell proliferation in thyroid cancer cells by suppressing expression of erb-b2 receptor tyrosine kinase 2 (10). Furthermore, miR-222 and miR-146b are positively correlated with the development of PTC in patients with recurrent PTC (14).

The abnormal expression of miR-22 has been widely reported in various types of cancer, including breast and colorectal cancers (15,16). However, whether miR-22 is dysregulated in PTC has not been investigated. The current study aimed to evaluate the expression of miR-22 in patients with PTC and to further elucidate whether it could be used as a potential biomarker to differentiate patients with PTC from patients with BTN and healthy controls.

Materials and methods

Patients

The present study was approved by the Research Ethics Committee of the Hongqi Hospital Affiliated to Mudanjiang Medical University (Mudanjiang, China) and all patients provided written informed consent. A total of 150 patients with primary PTC, 100 patients with BTN, and 40 age- and sex-matched healthy controls from the Hongqi Hospital Affiliated to Mudanjiang Medical University were enrolled in this study between April 2016 and November 2017. Written informed consent was obtained from all participants. PTC or BTN tissues were extracted from patients, 10% formalin-fixed at room temperature for 24 h and paraffin-embedded, and further analyzed for histopathological diagnosis and miRNA examination. The embedded samples were then immediately frozen for total RNA extraction. In addition, blood samples (5 ml) were taken from all subjects prior to surgery, and additional blood samples were collected from six patients after tumor resection and receiving appropriate treatment for 1 week. All blood samples were directly placed into tubes containing sodium citrate. Then, blood samples were centrifuged at 3,000 × g for 15 min at 4°C. Clinical features of the patients included in this study are listed in Table I.

Table I.

Clinical features of patients with PTC and healthy controls.

VariablePTC patientsBTN patientsHealthy controls
Male/female73/7752/4819/21
Age (year)55.3±11.349.5±16.253.8±7.9
Tumor size (cm)
  ≤177––
  >173––
Capsular invasion
  Yes62––
  No88––
Lymph node metastasis
  Yes65––
  No85––
No. of cancer foci
  Single86––
  Multiple74––
BRAFV600E gene
  Mutant98––
  Wild type52––

BRAF, B-Raf proto-oncogene serine/threonine kinase; BTN, benign thyroid nodule; PTC, papillary thyroid cancer.

US-guided FNAB

FNAB was performed to aspirate papillary thyroid tissues by endocrinologists using a 25-gauge needle. After each aspiration, the cytological material was immediately smeared onto slides. The slides were prepared by both air-dried and alcohol-fixed methods (70% alcohol once, 95% alcohol twice, absolute alcohol three times, each time for 1 min at room temperature). The air-dried smears were stained using the Diff-Quik method (17) and immediately evaluated by a cytopathologist, whereas the alcohol-fixed smears were stained by the Papanicolaou method (18) in the cytology laboratory. The sample slide obtained using the Diff-Quik method was then evaluated and classified as ‘adequate (sufficient lymphocytes),’ ‘less than optimal (some lymphocytes),’ or ‘inadequate (very few or no lymphocytes)’. Another FNA pass was performed without smear, and the sample was collected by rinsing the needle in a tube containing 1 ml Hank balanced salt solution without heparin. The specimens were immediately transferred to the clinical laboratory and stored at −20°C for 0 to 4 days prior to thyroglobulin (Tg) analysis. For each patient, all passes were performed by the same endocrinologist.

Tg-FNAB antibody assays

The Tg measurements in the needle washouts (Tg-FNAB) were carried out using a commercial immunofluorometric assay (TRA-1-81, Baiao Bolai Bio. Co, Beijing, China) with monoclonal antibodies (DELFIA®; PerkinElmer, Inc., Waltham, MA, USA) and a functional sensitivity of 1.0 ng/ml, according to the manufacturer's protocol.

Sample acquisition and RNA extraction

Total RNA from the serum and tissue samples was isolated with RNAVzol LS (Vigorous Biotechnology Co, Beijing, China, http://www.vigorousbiol.com/) according to the manufacturer's protocol. The quality, quantity and integrity of the RNA were monitored using a NanoDrop spectrophotometer (ND-1000; NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The RNA was reverse transcribed into cDNA using the Prime-Script one-step RT-qPCR kit referring to the M-MLV cDNA first strand synthesis system (cat no. C28025-032, Invitrogen; Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer's protocol. qPCR was performed using SYBR Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in a Bio-Rad iCycleriQ real-time PCR detection system. The qPCR procedure was performed as follows: 95°C for 10 min, followed by 50 cycles of 95°C for 10 sec, 55°C for 10 sec, 72°C for 5 sec, 99°C for 1 sec, 59°C for 15 sec and 95°C for 1 sec, after which, samples were cooled to 40°C. U6 was used as an internal reference gene. The relative expression levels were calculated using the 2−ΔΔCq method (19), and the experiments were repeated in triplicate. The primers used in the current study were as follows: miR-22-RT, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTAAGC-3′; U6-RT, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATG-3′; miR-22, forward, 5′-GCAGTTCTTCAGTGGCAAGC-3′; U6, forward, 5′-GCGCGTCGTGAAGCGTTC-3′; universal reverse primer, 5′-GTGCAGGGTCCGAGGT-3′. RT refers to the stem loop primer.

B-Raf proto-oncogene serine/threonine kinase (BRAF)V600E gene testing

Determination of the BRAFV600E gene mutation was carried out for all patients with PTC by PCR techniques (20). DNA was isolated from PTC tissues using a DNA Extraction kit (Promega Corporation, Madison, WI, USA), and BRAF gene exon 15 was detected using a BRAF mutant gene detection kit (Amoy Diagnostics Co., LTD, Fujian, China) according to the manufacturer's protocol and the ABI7500 real-time PCR amplifier (Applied Biosystems; Thermo Fisher Inc., Waltham, MA, USA). The primers for amplification of exon 15 of BRAF were designed as follows: Forward, 5′-TCATAATGCTTGCTCTGATAGGA-3′ and reverse, 5′-GGCCAAAAATTTAATCAGTGGA-3′). All procedures and analyses were carried out in the biomolecular laboratory of the Hongqi Hospital Affiliated to Mudanjiang Medical University.

Statistical analysis

Data are presented as the means ± standard deviation (SD). Each experiment was repeated with three times. A two-tailed unpaired Student's t-test was used for comparisons between two groups. One-Way Analysis of Variance (SPSS 13.0; SPSS, Inc., Chicago, IL, USA) followed by a Tukey post hoc test was used to compare more than two groups. Receiver operating characteristic (ROC) curves were used to assess miR-22 as a biomarker, and the area under the curve (AUC) was reported (SPSS version 20.0; IBM Corp., Armonk, NY, USA). Spearman's correlation coefficient was used to determine the correlation between serum miR-22 and tissue miR-22, and serum miR-22 and Tg levels in the tissues of patients with PTC. P<0.05 was considered to indicate a statistically significant difference.

Results

Serum miR-22 is increased in patients with PTC

RT-qPCR was carried out to detect the levels of miR-22 in the serum of patients with PTC, patients with BTN and healthy controls. Serum miR-22 was slightly increased in patients with BTN (1.67±1.18, P>0.05) whereas it was significantly increased in patients with PTC (24.65±6.58) compared with the healthy controls (1.00±0.58) (Fig. 1A). In addition, serum miR-22 was significantly increased in patients with PTC and metastasis (9.57±5.35) compared with in patients with PTC who have no metastasis (1.00±0.96) (P<0.01; Fig. 1B).

An external file that holds a picture, illustration, etc. Object name is ol-17-03-3355-g00.jpg

Serum miR-22 is enhanced in patients with PTC. (A) Serum miR-22 was slightly increased in patients with BTN and was significantly increased in patients with PTC compared with the healthy controls. (B) Serum miR-22 was significantly increased in patients with PTC and presenting metastasis compared with in patients with PTC who have no metastasis. **P<0.01, ***P<0.001 vs. healthy control; ###P<0.001 as indicated. BTN, benign thyroid nodule; miR-22, microRNA-22; PTC, papillary thyroid cancer.

Levels of miR-22 in thyroid tissue are increased in patients with PTC

Furthermore, miR-22 expression levels were increased in the thyroid tissue of patients with PTC (6.01±1.05) compared with in patients with BTN (1.00±0.56) (Fig. 2A). In addition, miR-22 was increased in patients with PTC and metastasis (3.86±0.85) compared with in patients with PTC who have no metastasis (1.00±0.42) (Fig. 2B). The correlation between serum and thyroid tissue levels of miR-22 was also investigated. Serum miR-22 levels were positively correlated with PTC tissue miR-22 levels (r=0.592, P<0.001; Fig. 2C).

An external file that holds a picture, illustration, etc. Object name is ol-17-03-3355-g01.jpg

Levels of miR-22 in thyroid tissue are increased in patients with PTC. (A) Expression levels of miR-22 were increased in the thyroid tissue from patients with PTC compared with in patients with BTN. (B) miR-22 was increased in the thyroid tissue from patients with PTC and metastasis compared with in patients with PTC who have no metastasis. (C) Spearman's correlation coefficient assay demonstrated that serum miR-22 levels were positively correlated with tissue miR-22 levels in patients with PTC. ***P<0.001 vs. BTN patients or non-metastatic patients. BTN, benign thyroid nodule; miR-22, microRNA-22; PTC, papillary thyroid cancer.

Serum miR-22 is enhanced in BRAFV600E mutant patients with PTC

Patients with PTC were further divided according to the presence of a BRAF gene mutation. As shown in Table I, 98 patients were identified as BRAFV600E mutants and 52 patients were identified as wild type BRAF patients. Furthermore, serum miR-22 levels were increased in the BRAFV600E mutant patients with PTC (18.86±5.12) compared with in the BRAFV600E wild type patients with PTC (1.00±0.79) (Fig. 3A). In addition, higher miR-22 levels were identified in the thyroid tissues of BRAFV600E mutant patients with PTC (6.87±1.35) compared with in the BRAFV600E wild type patients with PTC (1.00±0.65) (Fig. 3B).

An external file that holds a picture, illustration, etc. Object name is ol-17-03-3355-g02.jpg

Serum miR-22 is enhanced in BRAFV600E mutant patients with PTC. (A) Serum miR-22 levels were increased in the BRAFV600E mutant patients with PTC compared with in the BRAFV600E wild type patients with PTC. (B) Higher miR-22 levels were identified in the thyroid tissues from the BRAFV600E mutant patients with PTC compared with in the BRAFV600E wild type patients with PTC. ***P<0.001 vs. wild type patients. BRAF, B-Raf proto-oncogene serine/threonine kinase; miR-22, microRNA-22; PTC, papillary thyroid cancer.

miR-22 is positively correlated with Tg-FNAB levels

Tg determination in the needle washouts (Tg-FNAB) is an important method to determine malignancy in the lymph nodes (LNs). The serum expression levels of miR-22 were therefore compared in the different Tg-FNAB groups. Briefly, 30 patients were included in the ≤1 ng/ml Tg-FNAB group and 62 patients were included in the 1–10 ng/ml Tg-FNAB group, whereas 58 patients were included in >10 ng/ml Tg-FNAB group. As shown in Fig. 4A, serum miR-22 was much lower in patients with PTC with ≤1 ng/ml Tg-FNAB (1.00±0.64). Conversely, serum miR-22 was much higher in patients with PTC with 1–10 ng/ml Tg-FNAB (5.23±1.03) and was highest in patients with PTC with >10 ng/ml Tg-FNAB (16.24±4.36) (Fig. 4A). Furthermore, serum miR-22 was demonstrated to be positively correlated with Tg levels in patients with PTC (r=0.423, P<0.001; Fig. 4B).

An external file that holds a picture, illustration, etc. Object name is ol-17-03-3355-g03.jpg

miR-22 is positively correlated with Tg-FNAB levels. (A) Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was carried out to determine the serum expression levels of miR-22 in PTC patients with ≤1 ng/ml Tg-FNAB, 1–10 ng/ml Tg-FNAB and >10 ng/ml Tg-FNAB. (B) Spearman's correlation coefficient assay demonstrated that serum miR-22 was positively correlated with Tg levels in patients with PTC. ***P<0.001 vs. ≤1 ng/ml Tg; ##P<0.01 as indicated. miR-22, microRNA-22, PTC, papillary thyroid cancer; Tg-FNAB, thyroglobulin-fine needle aspiration biopsy.

miR-22 differentiates patients with PTC from healthy controls

Finally, a ROC analysis was carried out to evaluate whether serum miR-22 expression could be used as a potential biomarker to discern patients with PTC from healthy controls. Data revealed that serum miR-22 could differentiate patients with PTC from healthy controls, with an AUC of 0.942 (95% confidence interval: 0.858–1.000; P<0.001; Fig. 5).

An external file that holds a picture, illustration, etc. Object name is ol-17-03-3355-g04.jpg

Receiver operating characteristic analysis reveals that microRNA-22 differentiates patients with papillary thyroid cancer from healthy controls.

Discussion

The identification of novel biomarkers for patients with PTC is crucial (21,22). It has been reported that a BRAF mutation, assessed after FNA, is an important biomarker for aggressive PTC (23). Furthermore, p27, p21, cyclin D1, osteopontin and E-cadherin have also been suggested as potential biomarkers for the diagnosis of PTC (24,25). However, these biomarkers are limited due to their poor clinical applications.

Due to their stability and abundance in the circulatory system, circulating miRNAs have been revealed as important biomarkers for various types of cancer (11,12). To the best of our knowledge, the present study is the first to demonstrate increased miR-22 levels in the serum of patients with PTC compared with in patients with BTN and healthy controls. Similarly, the levels of miR-22 were increased in thyroid tissues of patients with PTC compared with in patients with BTN. These observations indicated that miR-22 may have an oncogenic role in the development of PTC. In addition, cancer metastasis is still a major cause of mortality for patients (26). Identifying a novel diagnostic tool or therapeutic intervention that would serve a key role in the prevention of PTC is therefore crucial (27). In the present study, serum and tissue miR-22 levels were significantly increased in patients with PTC and metastasis compared with in patients with PTC who had no metastasis.

The T1799A nucleotide mutation in the BRAF gene is a key oncogenic mutation in patients with PTC (28,29). It has been estimated that 45% of patients with PTC have this mutation, which corresponds to a valine-to-glutamic acid exchange in codon 600 of the BRAF protein (BRAFV600E). This mutation increases serine/threonine protein kinase activities and constitutively activates the mitogen-activated protein kinase signaling pathway (30,31). Therefore, BRAFV600E represents an important prognostic marker for patients with PTC (30,31). The expression levels of miR-22 in serum and tissue samples from patients with PTC and the BRAFV600E mutation were also analyzed and compared with the wild type patients. Results demonstrated that serum and tissue miR-22 levels were increased in patients with PTC with the BRAFV600E mutation, thus indicating that the upregulation of miR-22 may be positively associated with the risk of PTC.

Furthermore, Tg-FNAB is another important method for determining LN metastases (32,33). However, 5–10% of FNABs have been demonstrated to have non-diagnostic value and 6–8% to be false negatives (34). The present study revealed that serum miR-22 expression was significantly augmented in patients with PTC with 1–10 ng/ml Tg-FNAB and >10 ng/ml Tg-FNAB, thus suggesting that serum miR-22 may be used as an auxiliary non-invasive diagnostic method in line with Tg-FNAB levels. The ROC analysis also demonstrated that serum miR-22 expression was able to directly differentiate patients with PTC from healthy controls.

A previous study proposed that circulating miR-22 is associated with the etiology of liver injury in patients with human immunodeficiency virus (HIV), which suggests that miR-22 circulating levels may be an independent predictor of liver injury in patients with HIV (35). Furthermore, serum miR-22-5p is correlated with acute myocardial infarction (AMI), which suggests that miR-22 could also be a promising biomarker for the diagnosis of AMI (36). In comparison with these studies, the present study attempted to determine whether serum miR-22 expression could be a potential biomarker for patients with PTC. Other conditions may also cause an increase in serum miR-22 (1,2). The present study mainly focused on miR-22 expression in patients with PTC; a detailed analysis of miR-22 expression in serum and tissues was conducted from patients previously categorized into different groups. miR-22 levels were assessed in 150 patients with PTC, 100 patients with BTN and 40 normal subjects. The results revealed a significant increase in miR-22 expression in the serum and thyroid tissues of patients with PTC, which was associated with the presence of metastasis and the BRAFV600E mutation. ROC analysis also demonstrated that serum miR-22 may be used as a biomarker for screening patients with PTC. These novel findings are interesting and may be of significant clinical importance.

In conclusion, to the best of our knowledge, the present study was the first to reveal that miR-22 serum levels may represent a novel biomarker for patients with PTC that does not involve any invasive procedure. However, a larger number of samples should be included in a future study. In addition, detailed analysis of the potential relationship between serum levels of miR-22 and the clinicopathological features of patients should be considered.

Acknowledgements

Not applicable.

Funding

The present study was supported by a grant from the PhD startup fund of Mudanjiang Medical University (grant no. MMU-20170615).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

DW performed the experiments and analyzed the data. CG, TK, GM, and JL performed the RT-qPCR experiments. YS designed the experiments, analyzed the data and gave final approval of the published version. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Research Ethics Committee of Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang City (HQH-2016014, Mudanjiang City, China), and all the patients have provided written informed consent for this study.

Patient consent for publication

All patients provided consent for publication of their data.

Competing interests

The authors declare that they have no competing interests.

References

1. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:481–483. 10.1089/thy.2016.0628. [Abstract] [CrossRef] [Google Scholar]
2. Hao Y, Pan C, Chen W, Zhu WZ, Qi JP. Differentiation between malignant and benign thyroid nodules and stratification of papillary thyroid cancer with aggressive histological features: Whole-lesion diffusion-weighted imaging histogram analysis. J Magn Reson Imaging. 2016;44:1546–1555. 10.1002/jmri.25290. [Abstract] [CrossRef] [Google Scholar]
3. Fusco A, Chiappetta G, Hui P, Rostan GG, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: A search for the early precursors of papillary cancer. Am J Pathol. 2002;160:2157–2167. 10.1016/S0002-9440(10)61164-9. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
4. Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, Moses HL, Franco AT. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 2016;76:1804–1813. 10.1158/0008-5472.CAN-15-2351. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
5. Brace MD, Wang J, Petten M, Bullock MJ, Makki F, Trites J, Taylor SM, Hart RD. Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool? J Otolaryngol Head Neck Surg. 2014;43:22. [Europe PMC free article] [Abstract] [Google Scholar]
6. Hwang S, Shin DY, Kim EK, Yang WI, Byun JW, Lee SJ, Kim G, Im SJ, Lee EJ. Focal lymphocytic thyroiditis nodules share the features of papillary thyroid cancer on ultrasound. Yonsei Med J. 2015;56:1338–1344. 10.3349/ymj.2015.56.5.1338. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
7. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Falvo L, Vito CD, Catania A, Tartaglia F, Mocini R, Coccaro C, et al. Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. PLoS One. 2015;10:e0121514. 10.1371/journal.pone.0121514. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
8. Komatsu S, Ichikawa D, Takeshita H, Morimura R, Hirajima S, Tsujiura M, Kawaguchi T, Miyamae M, Nagata H, Hirotaka K, et al. Circulating miR-18a: A sensitive cancer screening biomarker in human cancer. In Vivo. 2014;28:293–297. [Abstract] [Google Scholar]
9. Kurashige J, Mima K, Sawada G, Takahashi Y, Eguchi H, Sugimachi K, Mori M, Yanagihara K, Yashiro M, Hirakawa K, et al. Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer. Carcinogenesis. 2015;36:133–141. 10.1093/carcin/bgu232. [Abstract] [CrossRef] [Google Scholar]
10. Wang XZ, Hang YK, Liu JB, Hou YQ, Wang N, Wang MJ. Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2. J Pharmacol Sci. 2016;130:78–84. 10.1016/j.jphs.2015.12.001. [Abstract] [CrossRef] [Google Scholar]
11. Chou CK, Liu RT, Kang HY. MicroRNA-146b: A novel biomarker and therapeutic target for human papillary thyroid cancer. Int J Mol Sci. 2017;18 10.3390/ijms18030636. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
12. Dai L, Wang Y, Chen L, Zheng J, Li J, Wu X. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer. World J Surg Oncol. 2017;15:11. 10.1186/s12957-016-1086-z. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
13. Xiong Y, Kotian S, Zeiger MA, Zhang L, Kebebew E. miR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. PLoS One. 2015;10:e0130496. 10.1371/journal.pone.0130496. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
14. Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG, Sidhu SB. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013;119:4358–4365. 10.1002/cncr.28254. [Abstract] [CrossRef] [Google Scholar]
15. Liu H, Huang X, Ye T. MiR-22 down-regulates the proto-oncogene ATP citrate lyase to inhibit the growth and metastasis of breast cancer. Am J Transl Res. 2018;10:659–669. [Europe PMC free article] [Abstract] [Google Scholar]
16. Chen Z, Shen A, Liu L, Chen Y, Chu J, Cai Q, Qi F, Sferra TJ, Peng J. Pien Tze Huang induces apoptosis and inhibits proliferation of 5-fluorouracil-resistant colorectal carcinoma cells via increasing miR-22 expression. Exp Ther Med. 2017;14:3533–3540. 10.3892/etm.2017.4951. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
17. Domper Arnal MJ, Ferrandez Arenas Á. and Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21:7933–7943. 10.3748/wjg.v21.i26.7933. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
18. Benjamin H, Schnitzer-Perlman T, Shtabsky A, VandenBussche CJ, Ali SZ, Kolar Z, Pagni F; Rosetta Genomics Group, Bar D and Meiri E: Analytical validity of a microRNA-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides. Cancer Cytopathol. 2016;124:711–721. 10.1002/cncy.21731. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. 10.1006/meth.2001.1262. [Abstract] [CrossRef] [Google Scholar]
20. Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, et al. Detection of BRAF V600 mutations in metastatic melanoma: Comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn. 2013;15:790–795. 10.1016/j.jmoldx.2013.07.003. [Abstract] [CrossRef] [Google Scholar]
21. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: Nondiagnostic cytologic results according to thyroid imaging reporting and data system before and after application of the bethesda system. Radiology. 2015;276:579–587. 10.1148/radiol.15142308. [Abstract] [CrossRef] [Google Scholar]
22. Moon HJ, Kim EK, Yoon JH, Kwak JY. Malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: Combination of thyroid imaging reporting and data system and the Bethesda System. Radiology. 2015;274:287–295. 10.1148/radiol.14140359. [Abstract] [CrossRef] [Google Scholar]
23. Zhang J, Liu BJ, Xu HX, Xu JM, Zhang YF, Liu C, Wu J, Sun LP, Guo LH, Liu LN, et al. Prospective validation of an ultrasound-based thyroid imaging reporting and data system (TI-RADS) on 3980 thyroid nodules. Int J Clin Exp Med. 2015;8:5911–5917. [Europe PMC free article] [Abstract] [Google Scholar]
24. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer. 2007;110:1218–1226. 10.1002/cncr.22912. [Abstract] [CrossRef] [Google Scholar]
25. Pesutic-Pisac V, Punda A, Gluncic I, Bedeković V. Kragić AP and Kunac N: Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: Association with clinicopathological parameters. Croat Med J. 2008;49:643–649. 10.3325/cmj.2008.5.643. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
26. Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8:30–40. [Europe PMC free article] [Abstract] [Google Scholar]
27. Baldini E, Sorrenti S, Tuccilli C, Prinzi N, Coccaro C, Catania A, Filippini A, Bononi M, Antoni ED, D'Armiento M, Ulisse S. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. Int J Surg. 2014;12(Suppl):S52–S56. 10.1016/j.ijsu.2014.05.054. [Abstract] [CrossRef] [Google Scholar]
28. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–627. 10.1093/jnci/95.8.625. [Abstract] [CrossRef] [Google Scholar]
29. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–1457. [Abstract] [Google Scholar]
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. 10.1038/nature00766. [Abstract] [CrossRef] [Google Scholar]
31. Millington GWM. Mutations of the BRAF gene in human cancer. Davies, et al. Clin Exp Dermatol. 2013;38:222–223. (Nature 2002; 417 949 54) [Abstract] [Google Scholar]
32. Li QK, Nugent SL, Straseski J, Cooper D, Riedel S, Askin FB, Sokoll LJ. Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma. Cancer Cytopathol. 2013;121:440–448. 10.1002/cncy.21285. [Abstract] [CrossRef] [Google Scholar]
33. Hanna AN, Michael CW, Jing X. Mixed medullary-follicular carcinoma of the thyroid: Diagnostic dilemmas in fine-needle aspiration cytology. Diagn Cytopathol. 2011;39:862–865. 10.1002/dc.21560. [Abstract] [CrossRef] [Google Scholar]
34. Frasoldati A, Valcavi R. Challenges in neck ultrasonography: Lymphadenopathy and parathyroid glands. Endocr Pract. 2004;10:261–268. 10.4158/EP.10.3.261. [Abstract] [CrossRef] [Google Scholar]
35. Anadol E, Schierwagen R, Elfimova N, Tack K, Schwarze-Zander C, Eischeid H, Noetel A, Boesecke C, Jansen C, Dold L, et al. Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients. Hepatology. 2015;61:46–55. 10.1002/hep.27369. [Abstract] [CrossRef] [Google Scholar]
36. Maciejak A, Kiliszek M, Opolski G, Segiet A, Matlak K, Dobrzycki S, Tulacz D, Sygitowicz G, Burzynska B, Gora M. miR-22-5p revealed as a potential biomarker involved in the acute phase of myocardial infarction via profiling of circulating microRNAs. Mol Med Rep. 2016;14:2867–2875. 10.3892/mmr.2016.5566. [Abstract] [CrossRef] [Google Scholar]
Articles from Oncology Letters are provided here courtesy of Spandidos Publications

Full text links 

Read article at publisher's site: https://doi.org/10.3892/ol.2019.10011

Read article for free, from open access legal sources, via Unpaywall: https://www.spandidos-publications.com/10.3892/ol.2019.10011/downloadUnpaywall

Citations & impact 

Impact metrics

11
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/126975280
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/126975280

Article citations

Go to all (11) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.